On the other hand, HR+ BC is generally less sensitive to cytotoxic chemotherapy, including neoadjuvant chemotherapy (NAC), when compared with HER2-positive (HER2+) BC and triple-negative breast cancer (TNBC) [9,10]. The gene discussed is ERBB2; the disease is breast cancer.